ARQT
Price
$26.20
Change
+$0.65 (+2.54%)
Updated
Nov 9 closing price
Capitalization
3.21B
112 days until earnings call
Intraday BUY SELL Signals
DMAC
Price
$9.65
Change
+$0.29 (+3.10%)
Updated
Nov 9 closing price
Capitalization
504.74M
2 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARQT vs DMAC

ARQT vs DMAC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARQT vs. DMAC commentary
Nov 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a StrongBuy and DMAC is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARQT with price predictions
Nov 09, 2026

Aroon Indicator for ARQT shows an upward move is likely

ARQT's Aroon Indicator triggered a bullish signal on November 09, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator showed a similar pattern. In 199 of the 222 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Following a +8.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in 249 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

ARQT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for ARQT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 28 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARQT as a result. In 70 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for ARQT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

ARQT moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.559) is normal, around the industry mean (3.498). ARQT has a moderately high P/E Ratio (116.136) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.435) is also within normal values, averaging (440.869).

A.I.Advisor
a Summary for DMAC with price predictions
Nov 09, 2026

DMAC's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for DMAC turned positive on October 22, 2026. Looking at past instances where DMAC's MACD turned positive, the stock continued to rise in 49 of 50 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DMAC as a result. In 84 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The 50-day moving average for DMAC moved above the 200-day moving average on October 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +6.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 218 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 131 of 159 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Bearish Trend Analysis

The 10-day RSI Indicator for DMAC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 24 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 58 cases where DMAC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

DMAC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.166) is normal, around the industry mean (3.498). P/E Ratio (-13.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
ARQT vs DMAC: Fundamental Ratings
ARQT
DMAC
OUTLOOK RATING
1..100
3338
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
8732
SMR RATING
1..100
5499
PRICE GROWTH RATING
1..100
4535
P/E GROWTH RATING
1..100
5682
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DMAC's Valuation (69) in the Biotechnology industry is in the same range as ARQT (99) in the null industry. This means that DMAC’s stock grew similarly to ARQT’s over the last 12 months.

DMAC's Profit vs Risk Rating (32) in the Biotechnology industry is somewhat better than the same rating for ARQT (87) in the null industry. This means that DMAC’s stock grew somewhat faster than ARQT’s over the last 12 months.

ARQT's SMR Rating (54) in the null industry is somewhat better than the same rating for DMAC (99) in the Biotechnology industry. This means that ARQT’s stock grew somewhat faster than DMAC’s over the last 12 months.

DMAC's Price Growth Rating (35) in the Biotechnology industry is in the same range as ARQT (45) in the null industry. This means that DMAC’s stock grew similarly to ARQT’s over the last 12 months.

ARQT's P/E Growth Rating (56) in the null industry is in the same range as DMAC (82) in the Biotechnology industry. This means that ARQT’s stock grew similarly to DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARQTDMAC
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 11 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
COMPARISON
Comparison
Nov 10, 2026
Stock price -- (ARQT: $25.55 vs. DMAC: $9.36)
Brand notoriety: ARQT and DMAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 100% vs. DMAC: 63%
Market capitalization -- ARQT: $3.21B vs. DMAC: $504.74M
ARQT [@Biotechnology] is valued at $3.21B. DMAC’s [@Biotechnology] market capitalization is $504.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 0 FA rating(s) are green while DMAC’s FA Score has 1 green FA rating(s).

  • ARQT’s FA Score: 0 green, 5 red.
  • DMAC’s FA Score: 1 green, 4 red.
According to our system of comparison, DMAC is a better buy in the long-term than ARQT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 4 TA indicator(s) are bullish while DMAC’s TA Score has 5 bullish TA indicator(s).

  • ARQT’s TA Score: 4 bullish, 6 bearish.
  • DMAC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than ARQT.

Price Growth

ARQT (@Biotechnology) experienced а -20.33% price change this week, while DMAC (@Biotechnology) price change was +1.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.

Reported Earning Dates

ARQT is expected to report earnings on Mar 02, 2027.

DMAC is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+2.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ARQT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with PTGX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
+2.54%
PTGX - ARQT
48%
Loosely correlated
+2.92%
XNCR - ARQT
46%
Loosely correlated
+7.94%
PTCT - ARQT
45%
Loosely correlated
-0.63%
TGTX - ARQT
43%
Loosely correlated
+5.94%
DMAC - ARQT
43%
Loosely correlated
+3.10%
More

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with ANNX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then ANNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+3.10%
ANNX - DMAC
47%
Loosely correlated
+0.71%
EDIT - DMAC
47%
Loosely correlated
+7.00%
TSHA - DMAC
45%
Loosely correlated
+0.92%
VIR - DMAC
44%
Loosely correlated
+11.75%
SLDB - DMAC
44%
Loosely correlated
+6.53%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
WAR25.751.42
+5.84%
U.S. Global Technology and Aerospace and Defense ETF
HOOW17.480.50
+2.94%
Roundhill HOOD WeeklyPay ETF (HOOW)
BOCT54.690.96
+1.79%
Innovator U.S. Equity Buffer ETF - October (BOCT)
DHS119.091.60
+1.36%
WisdomTree U.S. High Dividend Fund (DHS)
SUPL44.83N/A
N/A
ProShares Supply Chain Logistics ETF (SUPL)